A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC)

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Mesenchymal Epithelial Transition Factor ◽

Mesenchymal Epithelial Transition

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2016.190 ◽

2017 ◽

Vol 32 (3) ◽

pp. 422-428 ◽

Cited By ~ 1

Author(s):

Yong Won Choi ◽

Jin-Hyuk Choi

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Significance of Sequential Treatment with Afatinib in the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment of Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3935 ◽

2019 ◽

Author(s):

N. Kobayashi ◽

H. Aiko ◽

C. Kamimaki ◽

N. Mikami ◽

S. Kubo ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant

Pneumonitis in advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI): Meta-analysis of 153 trial cohorts with 15,713 pts.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21223 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21223-e21223

Author(s):

Chong Hyun Suh ◽

Hyesun Park ◽

Kyung Won Kim ◽

Junhee Pyo ◽

Hiroto Hatabu ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyz023 ◽

2019 ◽

Vol 49 (6) ◽

pp. 554-558 ◽

Cited By ~ 5

Author(s):

Kazuhiro Usui ◽

Takuma Yokoyama ◽

Go Naka ◽

Hiroo Ishida ◽

Kazuma Kishi ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutant ◽

Inhibitor Treatment

Case Report: A Rare Epidermal Growth Factor Receptor (EGFR) H773L/V774M Compound Mutation in Advanced Non-Small Cell Lung Cancer with Poor Response to EGFR Tyrosine Kinase Inhibitor

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6993 ◽

2019 ◽

Author(s):

L.-C. Chen ◽

C.-Y. Yang

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Poor Response ◽

Small Cell ◽

Small Cell Lung ◽

Compound Mutation ◽

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Combined with Chemoradiotherapy for the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer

Haigan ◽

10.2482/haigan.46.261 ◽

2006 ◽

Vol 46 (3) ◽

pp. 261-265

Author(s):

Yuichiro Ohe

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

BMJ Case Reports ◽

10.1136/bcr.06.2008.0075 ◽

2008 ◽

Vol 2008 (nov12 1) ◽

pp. bcr0620080075-bcr0620080075 ◽

Cited By ~ 1

Author(s):

R. K Shrimali ◽

P. D Correa ◽

M. Rizwanullah

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups

Experimental and Therapeutic Medicine ◽

10.3892/etm.2020.8612 ◽

2020 ◽

Author(s):

Qiao Zhang ◽

Yanyan Cui ◽

Jian Zhang ◽

Jiayideng Kenjiabieke ◽

Patiguli Aerxiding

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Epidermal Growth ◽

Inhibitor Treatment

Neutrophil to lymphocyte ratio (NLR) as a predictive marker of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutation-positive non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19117 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19117-e19117

Author(s):

Gayatri Vaidyanathan ◽

Grace K. Dy ◽

Petr Starostik ◽

Shiva Dibaj

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Predictive Marker ◽

Small Cell ◽

Small Cell Lung ◽

Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robustin vivoantitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2021-1467 ◽

2021 ◽

Author(s):

Sun Min Lim ◽

Chae Won Park ◽

Zhuo Zhang ◽

Rich Woessner ◽

Tom Dineen ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Fourth Generation ◽

Small Cell Lung ◽